Result Filters
CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Author(s):
- CADTH Canadian Drug Expert Committee, author
- Canadian Agency for Drugs and Technologies in Health, issuing body
- Title(s):
- CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Other Title(s):
- Guselkumab (Tremfya -- janssen inc.)
- Series:
- CADTH common drug review
- Edition:
- Version 1.0.
- Country of Publication:
- Canada
- Publisher:
- Ottawa (ON) : CADTH, February 21, 2018.
- Description:
- 1 online resource (1 PDF file (9 pages)).
-
Language:
- English
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK532985/
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks.
- MeSH:
- Antibodies, Monoclonal/economics
Antibodies, Monoclonal/therapeutic use
Canada
Drug Costs
Insurance, Health, Reimbursement
Interleukin-23 Subunit p19/economics
Interleukin-23 Subunit p19/therapeutic use
Psoriasis/drug therapy*
- Notes:
- "Final."
Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- Other ID:
- (OCoLC)1090385001
- NLM ID:
- 101740710 [Electronic Resource]